') no-repeat 50% 50%;margin-left:.625rem;content:""}.dropdown-item:disabled{color:#999;background-color:transparent;cursor:default;pointer-events:auto}.check-container .checkbox input:checked~span:after,.check-container .checkbox span:checked:after{opacity:1}.dropdown-item xetf-icon{transition:transform .15s ease-in}.dropdown-item>xetf-icon{margin-right:.625rem}.dropdown-toggle{display:flex!important;align-items:center;font-size:.875rem}.dropdown-toggle:after{background-color:currentColor;-webkit-mask-size:cover;mask-size:cover;transform:rotate(0);transition:transform .1s}.dropdown-toggle:not([class*=btn-]):focus,.dropdown-toggle:not([class*=btn-]):hover{color:#2196f3;font-weight:500;background-color:inherit}.check-container .check-label:not(:has(b)),.text-check a{font-weight:600}.form-control{height:calc(1.6568em + 1.25rem + 2px);background-clip:border-box;-webkit-appearance:none;filter:none}.form-control:-webkit-autofill,.form-control:-webkit-autofill:active,.form-control:-webkit-autofill:focus,.form-control:-webkit-autofill:hover{box-shadow:0 0 0 30px #fff inset!important}.form-control:disabled{color:#999;background-color:#f5f5f5}.form-control,.form-control:focus,.form-control:focus-visible{box-shadow:none}.input-group-sm .form-control{height:2.10419375rem}.form-check-new{position:relative;display:flex}.form-check-new+.form-check-new{margin-top:.625rem}.form-check-new:not(.inline){margin-bottom:.25rem}.form-check-new:not(.inline)>xetf-checkbox{margin-right:.875rem}.text-check{line-height:1.5;font-size:.75rem;color:#444;padding-top:1px}.text-check.sm{font-size:.625rem;padding-top:2px}.check-container{display:flex;align-items:center;margin-bottom:0;cursor:pointer}.cursor-pointer,.navbar-nav-link,.navbar-toggler,a{cursor:pointer}.check-container:not(.disabled):hover{color:#666}.check-container .checkbox,.check-container .checkbox input,.check-container .checkbox span{width:var(--checkbox-size);height:var(--checkbox-size)}.check-container .checkbox input{border:0;background:0 0;display:inline-block;margin:0;cursor:pointer;position:absolute;visibility:visible;opacity:0;z-index:2}.check-container .checkbox input:focus~span,.check-container .checkbox input:hover~span{box-shadow:0 4px 4px #0000001f}.check-container .checkbox span{display:inline-block;position:relative;text-align:center;border-style:solid;border-color:#999;color:#42a5f5;transition:box-shadow .15s ease-in}a.text-default:not(.btn){transition:color .15s ease-in-out}.check-container .checkbox span:after{content:"";position:absolute;opacity:0;transition:opacity .15s ease-in}.check-container .checkbox+:not(:empty){margin-left:1rem;line-height:1;text-align:left;transition:color .15s ease-in-out}.rotate-180{transform:rotate(180deg)}.w-100{width:100%!important}.shadow-0{box-shadow:none!important}.text-underline{text-decoration:underline}.hidden{visibility:hidden}.nowrap{white-space:nowrap}.bg-primary-50{background-color:#e4f4fe!important}.input-group{margin-bottom:1.25rem}.input-group .form-control::placeholder{color:#aaa;font-weight:500}.input-group .form-control::-webkit-search-cancel-button{display:none}.input-group .form-control::-webkit-inner-spin-button,.input-group .form-control::-webkit-outer-spin-button{-webkit-appearance:none;margin:0}.input-group:focus-within .input-group-text{border-color:#999}.input-group-text{font-weight:500;transition:border-color .15s ease-in-out,box-shadow .15s ease-in-out}.input-group-text xetf-icon{color:#bbb;font-size:.9375rem;z-index:4}.input-group-text:first-child{border-right:0;border-top-right-radius:0;border-bottom-right-radius:0}.input-group-text+.form-control{border-left:0}.input-group-text+.form-control{padding-left:0}.input-group-text+.form-control:disabled{border-left-width:0;padding-left:2.625rem!important;margin-left:-2.625rem!important}html{display:flex;scroll-behavior:smooth}body{min-height:100vh;display:flex;flex-direction:column;flex:1}.content{padding:3rem .625rem;flex-grow:1;z-index:1}app-root{transition:.15s ease-in}.navbar,.navbar .dropdown-item{font-size:.75rem}.toolbar-main-items{overflow-x:auto;overflow-y:hidden;scrollbar-width:none}.toolbar-main-items:after,.toolbar-main-items:before{content:"";position:absolute;top:0;width:30px;height:40px;z-index:1;transition:box-shadow .3s;pointer-events:none}.toolbar-main-items:before{left:0}.toolbar-main-items:after{right:0}.toolbar-main-items::-webkit-scrollbar{display:none}.toolbar-container{display:flex;flex-wrap:wrap;position:relative}.toolbar-container .toolbar-main-items{height:40px}.toolbar-container .toolbar-main-items{position:static;flex:1 0 100%}.new-navbar-collapse{position:absolute;inset:2.25rem 0 auto!important;z-index:600;padding:1.25rem 0;background-color:#324148;transform:translateY(-520px);will-change:transform;transition:transform .3s ease-in}.navbar .nav-item>a,.navbar-nav-link{position:relative}.navbar-nav-link,.navbar-toggler{transition:.15s ease-in-out}.new-navbar-collapse .dropdown-menu{overflow:hidden;border-top-left-radius:.3125rem;border-top-right-radius:.3125rem}.navbar{font-weight:600}.navbar .dropdown-menu,.navbar .dropdown-toggle,.navbar .navbar-nav-link{font-size:.75rem;white-space:nowrap}.navbar .dropdown-toggle:hover{font-weight:600}.navbar-brand img{height:1.625rem;aspect-ratio:4.254;display:block}.navbar-nav{justify-content:space-evenly}.navbar-nav-link{display:flex;padding:1rem 1.75rem}.navbar-toggler{z-index:601;border:0;padding:.75rem 10px}.navbar-toggler:last-child{margin-right:-15px}@media (max-width:1199.98px){.navbar-brand img{height:1.25rem}.navbar-expand-xl .navbar-nav-link.dropdown-toggle:after{position:absolute;right:calc(1.5rem + 7px);margin:0}.navbar-expand-xl .navbar-nav>.nav-item>.dropdown-menu{width:100%;border-radius:0}}.navbar-dark{--bs-navbar-color:#fff;--bs-navbar-hover-color:#fff;--bs-navbar-disabled-color:rgba(255, 255, 255, .5);--bs-navbar-active-color:#fff;--bs-navbar-brand-color:#fff;--bs-navbar-brand-hover-color:#fff;--bs-navbar-toggler-border-color:rgba(255, 255, 255, .1);--bs-navbar-toggler-icon-bg:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 30 30'%3e%3cpath stroke='%23fff' stroke-linecap='round' stroke-miterlimit='10' stroke-width='2' d='M4 7h22M4 15h22M4 23h22'/%3e%3c/svg%3e");color:#fff;background-color:#324148}.sidebar-light{background-color:#fff}.navbar-dark .navbar-nav-link{color:#fff;padding:1rem}.navbar-dark .navbar-nav-link:focus,.navbar-dark .navbar-nav-link:hover{color:#fff;background-color:#00000026}.sidebar{flex:0 0 auto;width:18.75rem;z-index:1040}.sidebar-light{color:#324148;border-right:1px solid rgba(0,0,0,.125);background-clip:content-box}.sidebar-component{display:none;width:100%;border:1px solid transparent;border-radius:5px;box-shadow:0 4px 4px #0000001a,0 4px 8px #2220410d,0 0 4px #2220411a,0 0 4px #2220411a}.sidebar-component.sidebar-light{border-color:#00000020}h1,h2,h3{letter-spacing:-.015em;font-weight:700}.text-default{color:#324148!important}a.text-default:focus,a.text-default:hover{color:#324148bf}.dropdown-menu.newsletter-dropdown{padding:1rem 1.125rem}.app-container{width:100%;margin:0 auto}.route-loader{position:fixed;top:0;width:100%;z-index:10000}.route-loader .progress{background-color:#0000}.route-loader .progress .progress-bar{position:absolute;height:100%;transition:width 5s linear;animation:3s infinite increase}.route-loader.hidden>.progress{height:0;opacity:0}@keyframes increase{0%{transform:translate(-100%);width:5%}to{transform:translate(250%);width:40%}}.btn>xetf-icon{transition:transform .15s ease-in-out}.auth-offer-container{position:relative;display:block;min-height:150px}
AKTIE IM FOKUS: Fresenius auf Zweimonatshoch - Tyenne-Einführung ein Meilenstein Von dpa-afx.de 16. April 2024 AKTIE IM FOKUS: Fresenius auf Zweimonatshoch - Tyenne-Einführung ein Meilenstein
FRANKFURT (dpa-AFX) - Aktien von Fresenius (Profil) haben sich am Dienstag erfolgreich dem Negativtrend im Dax <DE0008469008> entzogen. Die Papiere der Bad Homburger erklommen mit einem Plus von gut 3,5 Prozent das höchste Niveau seit rund zwei Monaten.
Fresenius gab am Vorabend die US-Markteinführung des Biosimilar Tyenne bekannt. Dabei handelt es sich um ein Nachahmerprodukt des zuvor patentgeschützten Antikörpers Tocilizumab gegen verschiedene Autoimmunerkrankungen.
Laut dem DZ-Bank-Experten Sven Kürten kommt die Markteinführung etwas früher, als er erwartet hatte. Die Nachricht zeige, dass Fresenius weiter auf einem sehr guten Weg sei. Direkte Auswirkungen auf seine Gewinnprognosen sieht er allerdings nicht./ag/jha/
Die dpa-AFX Wirtschaftsnachrichten GmbH zählt zu den führenden Nachrichtenagenturen für Finanz- und Wirtschaftsnachrichten in deutscher und englischer Sprache. Mit ihrem weltweiten Journalisten-Netzwerk berichtet dpa-AFX unabhängig, zuverlässig und schnell über das internationale Finanz- und Wirtschaftsgeschehen.
Bitte Javascript aktivieren